Clinical trials: Non Small Cell Lung Cancer Stage IIIB
Lung Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004160
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Alabama at Birmingham
Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with clinico-pathological…
- Trial name
- REASON (NCT00997230)
- Where
- 118 sites in Germany
- Volunteers
- 4,243 people
- Sponsor
- AstraZeneca
Breast Cancer, Colorectal Cancer
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01212887
- Testing
- MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
Lung Cancer
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Trial name
- NCT00661193
- Testing
- carboplatin, erlotinib hydrochloride, paclitaxel
- Where
- 124 sites in United States
- Volunteers
- 59 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin, paclitaxel, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00738452
- Testing
- high performance liquid chromatography, pharmacological study, radionuclide imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Neoadjuvant Non-Small Cell Lung Cancer
Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer
This project was designed To explore the pathological complete response (pCR) of lorlatinib as neoadjuvant treatment. Twenty-five patients will be involved in this study.
- Trial name
- NEOLORA (NCT06682884)
- Testing
- Lorlatinib 100 mg
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Anorexia, Lung Non-Small Cell Carcinoma
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
This phase II/III trial studies how well anamorelin hydrochloride works in reducing anorexia in patients with non-small cell lung cancer that has spread to other places in the body.
- Conditions
- Anorexia, Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03637816
- Testing
- Anamorelin Hydrochloride, Questionnaire Administration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer Stage IIIB
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab.
- Trial name
- NCT03302247
- Testing
- Nivolumab, Nivolumab+Gemcitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Lung Cancer
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00469976
- Testing
- bevacizumab, carboplatin, enzastaurin hydrochloride
- Sponsor
- Eastern Cooperative Oncology Group
Carcinoma, Non-Small Cell Lung
A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
This is a Phase II, multicenter, double-blind, randomized study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab in combination with platinum-doublet chemotherapy followed by atezolizumab…
- Trial name
- CATHAYA (NCT04611776)
- Testing
- Atezolizumab, Carboplatin, Cisplatin
- Sponsor
- Hoffmann-La Roche
Squamous Non-small Cell Lung Cancer
Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Envafolimab combined with standard platinum containing dual drug chemotherapy and Recombinant Human Endostatin in…
- Trial name
- NCT05243355
- Testing
- "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
- Where
- 2 sites in China
- Volunteers
- 46 people
- Sponsor
- Qilu Hospital of Shandong University
Colorectal Cancer, Lung Cancer
AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00343408
- Testing
- cediranib maleate, cisplatin, fluorouracil
- Where
- 3 sites in Canada
- Volunteers
- 31 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether giving chemotherapy in addition to standard therapy is a more effective treatment for…
- Trial name
- NCT00003240
- Testing
- cisplatin, ifosfamide, mitomycin C
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, EGFR Sensitive Mutation
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive…
- Conditions
- Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
- Trial name
- NCT06041776
- Where
- 3 sites in China
- Volunteers
- 570 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Tumors
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients…
- Trial name
- FALCON (NCT00653939)
- Testing
- Fosbretabulin, Carboplatin, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mateon Therapeutics
Non-Small Cell Lung Cancer, Carcinoma
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
This first time in human study is intended for men and women at least 18 years of age who have advanced lung cancer which has grown or returned after being treated.
- Trial name
- NCT02592577
- Testing
- Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 28 people
- Sponsor
- Adaptimmune
Lung Cancer
Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004139
- Testing
- docetaxel, gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose…
- Trial name
- SELECT-2 (NCT01750281)
- Testing
- Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2
- Where
- 68 sites in United States, Brazil and 6 more
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.